Skip to content
  • About us
    • Advisory Board
    • Our mission
    • GDPR Policy
  • Editorial guidelines
    • Peer-review protocol
    • Author guidelines
    • Editorial Calendar 2018
    • Editorial Calendar 2017
  • Advertise with us
    • Media Information 2021
    • Media Information 2020
  • Subscribe
    • weekly newsletter
  • Contact Us
secondary menu
Journal for Clinical Studies
Journal for Clinical StudiesJournal for Clinical Studies

  • Home
  • Current features/ Volume 12 Issue 6
  • Editorial Archive
    • Volume 12 Issue 5
    • Volume 12 Issue 4
    • Volume 12 Issue 3
    • Volume 12 Issue 2
    • Volume 12 Issue 1
    • Volume 11 Issue 6
    • Volume 11 Issue 5
    • Volume 11 Issue 4
    • Volume 11 Issue 3
    • Volume 11 Issue 2
    • Volume 11 Issue 1
    • Volume 10 Issue 6
    • Volume 10 Issue 5
    • Volume 10 Issue 4
    • Volume 10 Issue 3
    • Volume 10 Issue 2
    • Volume 10 Issue 1
    • Volume 9 Issue 6
      • Volume 10 Issue 6
    • Volume 9 Issue 5
    • Volume 9 Issue 4
    • Volume 9 Issue 3
    • Volume 9 Issue 2
    • Volume 9 Issue 1
      • Regulatory V9 I1
      • Market Report V9 I1
      • Therapeutics V9 I1
      • IT & Logistics V9 I1
    • Volume 8 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Technology
      • Therapeutics
      • Special Features
      • Logistics
    • Volume 8 Issue 5
      • Watch Pages V8 I5
      • Regulatory V8 I5
      • Market Report V8 I5
      • Technology V8 I5
      • Therapeutics V8 I5
      • Special Features V8 I5
      • Logistics V8 I5
    • Volume 8 Issue 4
      • Watch Pages V8 I4
      • Regulatory V8 I4
      • Market Report V8 I4
      • Therapeutics V8 I4
      • Technology V8 I4
      • Logistics V8 I4
      • Special Feature V8 I4
    • Volume 8 Issue 3
      • Watch Pages V8 I3
      • Regulatory V8 I3
      • Market Report V8 I3
      • Therapeutics V8 I3
      • Technology V8 I3
      • Logistics V8 I3
      • Special Feature V8 I3
    • Volume 8 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 8 Issue 1
    • Volumen 8 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 issue 3
      • Watch Pages
      • Therapeutics
      • Research & Development
      • Regulatory & Marketplace
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • Technology
      • Logistics
    • Volume 7 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • Technology
      • Logistics
    • Volume 6 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 3
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • It & Logistics
      • Special Features
    • Volume 6 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 5 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • It & Logistics
      • Therapeutics
      • Special Features
    • Volume 5 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 5 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Feature
    • Volume 5 Issue 3
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
  • Archived Issues
  • Industry events
  • Company Profile
    • A-D
    • E-M
    • N-S
    • T-Z
  • Regional News
    • Asia Pacific
    • Australasia
    • Europe
    • Latin America
    • MEANA Region
    • North America
    • Russia/Eastern Europe
    • Scandinavia
    • South Africa
    • Sub Saharan Africa
  • eBooks
  • Home
  • Current features/ Volume 12 Issue 6
  • Editorial Archive
    • Volume 12 Issue 5
    • Volume 12 Issue 4
    • Volume 12 Issue 3
    • Volume 12 Issue 2
    • Volume 12 Issue 1
    • Volume 11 Issue 6
    • Volume 11 Issue 5
    • Volume 11 Issue 4
    • Volume 11 Issue 3
    • Volume 11 Issue 2
    • Volume 11 Issue 1
    • Volume 10 Issue 6
    • Volume 10 Issue 5
    • Volume 10 Issue 4
    • Volume 10 Issue 3
    • Volume 10 Issue 2
    • Volume 10 Issue 1
    • Volume 9 Issue 6
      • Volume 10 Issue 6
    • Volume 9 Issue 5
    • Volume 9 Issue 4
    • Volume 9 Issue 3
    • Volume 9 Issue 2
    • Volume 9 Issue 1
      • Regulatory V9 I1
      • Market Report V9 I1
      • Therapeutics V9 I1
      • IT & Logistics V9 I1
    • Volume 8 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Technology
      • Therapeutics
      • Special Features
      • Logistics
    • Volume 8 Issue 5
      • Watch Pages V8 I5
      • Regulatory V8 I5
      • Market Report V8 I5
      • Technology V8 I5
      • Therapeutics V8 I5
      • Special Features V8 I5
      • Logistics V8 I5
    • Volume 8 Issue 4
      • Watch Pages V8 I4
      • Regulatory V8 I4
      • Market Report V8 I4
      • Therapeutics V8 I4
      • Technology V8 I4
      • Logistics V8 I4
      • Special Feature V8 I4
    • Volume 8 Issue 3
      • Watch Pages V8 I3
      • Regulatory V8 I3
      • Market Report V8 I3
      • Therapeutics V8 I3
      • Technology V8 I3
      • Logistics V8 I3
      • Special Feature V8 I3
    • Volume 8 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 8 Issue 1
    • Volumen 8 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 issue 3
      • Watch Pages
      • Therapeutics
      • Research & Development
      • Regulatory & Marketplace
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • Technology
      • Logistics
    • Volume 7 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • Technology
      • Logistics
    • Volume 6 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 3
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • It & Logistics
      • Special Features
    • Volume 6 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 5 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • It & Logistics
      • Therapeutics
      • Special Features
    • Volume 5 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 5 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Feature
    • Volume 5 Issue 3
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
  • Archived Issues
  • Industry events
  • Company Profile
    • A-D
    • E-M
    • N-S
    • T-Z
  • Regional News
    • Asia Pacific
    • Australasia
    • Europe
    • Latin America
    • MEANA Region
    • North America
    • Russia/Eastern Europe
    • Scandinavia
    • South Africa
    • Sub Saharan Africa
  • eBooks
Breaking News
  • CPhI Worldwide Announces New November 2021 Dates ...January 15, 2021
  • Japan’s Kobayashi Kako admits manufacturing mix-u ...December 21, 2020
  • AbbVie’s Botox wins reprieve as agency bars Evolu ...December 21, 2020
  • MacroGenics HER2 drug scores FDA breast cancer nod with ...December 21, 2020
  • Lilly and Regeneron COVID-19 antibodies are available a ...December 21, 2020

Daily Archives: 13th December 2017

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

newsBy flabio513th December 2017

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment…

CTI Clinical Trial, Consulting Services Announces Acquisition Of Eurotrials

newsBy flabio513th December 2017

CTI Clinical Trial and Consulting Services announced the acquisition of Eurotrials, a full-service contract research organization, with more than 20…

CRISPR Therapeutics Announces Planned European Clinical Trial

newsBy flabio513th December 2017

CRISPR Therapeutics today announced the submission of a Clinical Trial Application (CTA) today for CTX001 in β-thalassemia. CTX001 is an…

Bioethics International Releases Second Good Pharma Scorecard

newsBy flabio513th December 2017

Bioethics International announced the second publication of its Good Pharma Scorecard (“GPS”), an annual index ranking large pharmaceutical companies and…

Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma

newsBy flabio513th December 2017

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from a pivotal Phase 2 clinical study of…

JW Pharma releases cancer treatment trial results

newsBy flabio513th December 2017

South Korea based JW Pharmaceuticals recently presented phase 1a/1b clinical trial results for CWP291, a target anticancer treatment that uses…

Ablynx has announced additional results from the Phase III Hercules study with caplacizumab

newsBy flabio513th December 2017

Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced additional results from the Phase III HERCULES study with caplacizumab, the…

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

newsBy flabio513th December 2017

Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical…

Roche announces Phase III study results for the treatment of people with advanced kidney cancer

newsBy flabio513th December 2017

Roche has announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated…

© 2020 Jforcs Media, All Rights Reserved. Powered by Teksyte LTD
Go to Top
This site uses cookies and by using the site you are consenting to this. Find out why we use cookies and how to manage your settings. Full details can be found here. Read More Accept
Privacy & Cookies Policy
Necessary Always Enabled